Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

130.03 +3.03 (+2.38%)
Streaming Delayed Price Updated: 12:41 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,246,008
Open 129.69
Bid (Size) 130.01 (2)
Ask (Size) 130.04 (3)
Prev. Close 127.00
Today's Range 128.76 - 132.80
52wk Range 99.14 - 133.10
Shares Outstanding 2,531,374,696
Dividend Yield 2.25%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
S&P 500 Down Over 1%; Merck Increases 2024 Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024
MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+14.82%
+14.82%
1 Month
+3.76%
+3.76%
3 Month
+9.38%
+9.38%
6 Month
+25.47%
+25.47%
1 Year
+11.58%
+11.58%

More News

Read More
Meta Falls 15% On Great Earnings, Tesla Rises 12% On Ugly Earnings – Here Is The Real Reason
Via Benzinga
Merck Rides Keytruda To Another Beat-And-Raise, But Diabetes Headwinds Persist
Via Investor's Business Daily
Merck Announces First-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
3 Under-The-Radar Stocks With Positive Potential
Via Talk Markets
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Via Benzinga
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Via Benzinga
Unveiling 17 Analyst Insights On Merck & Co
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Investor Alert: Prepare for the Market Crash With These 3 Stocks
Via InvestorPlace
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
Via InvestorPlace
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
Via InvestorPlace
Exposures Product Safety
3 Dow Stocks to Buy Now: Q2 Edition
Via InvestorPlace
Topics Stocks
Exposures US Equities
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Via Talk Markets
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
Via The Motley Fool
1 New Green Flag for Moderna and Merck Stock
Via The Motley Fool
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
Via InvestorPlace
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
Via Benzinga
Exposures COVID-19
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.